The Pharmacogene Variation Consortium (PharmVar) catalogues star (*) allele
nomenclature for the polymorphic human CYP2C19 gene. CYP2C19 genetic variation …

The present study evaluates the worldwide frequency distribution of CYP2C19 alleles and
CYP2C19 metabolic phenotypes ('predicted'from genotypes and 'measured'with a probe …

The cytochrome P450, family 2, subfamily C, polypeptide 19 (CYP2C19) gene is located
within a cluster of cytochrome P450 genes (centromere-CYP2C18-CYP2C19-CYP2C9 …

Variability in response to antiplatelet therapy can be explained in part by
pharmacogenomics, particularly of the CYP450 enzyme encoded by CYP2C19. Loss-of …

Genetic diversity is greater in Africa than in other continental populations. Genetic variability
in genes encoding drug metabolizing enzymes may contribute to the high numbers of …

Both safety and efficacy of medical treatment can vary depending on the ethnogeographic
background of the patient. One of the reasons underlying this variability is differences in …

Human genetic studies have long been vastly Eurocentric, raising a key question about the
generalizability of these study findings to other populations. Because humans originated in …

Background Warfarin dose variability observed in patients is attributed to variation in genes
involved in the warfarin metabolic pathway. Genetic variation in CYP2C9 and VKORC1 has …

Proton pump inhibitors (PPIs) are used widely for the treatment of acid-related disorders.
Despite their excellent efficacy and tolerance, the pharmacodynamics and pharmacokinetics …

South Africa, like many other developing countries, stands to benefit from novel diagnostics
and drugs developed by pharmacogenomics guidance due to high prevalence of disease …